AiCuris (Germany)

Recent papers from AiCuris (Germany)

1. Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 TrialOpen Forum Infectious Diseases · 2026
2. Neonicotinoids with a 6‐chloropyridinyl group (e.g. imidacloprid, acetamiprid, thiacloprid, nitenpyram, boscalid) – Determination of 6‐chloronicotinic acid in urine by GC‐MS2026
3. P-113. Interim Results of the First-in-human Phase 1 Trial of AIC468: A Novel Antisense Oligonucleotide that Targets BK-Virus TranscriptsOpen Forum Infectious Diseases · 2026
4. Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjectsOpen Forum Infectious Diseases · 2026
5. Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus InfectionNucleic Acid Therapeutics · 2025
6. Discovery of AIC263282, a Hepatitis B Virus Capsid Assembly Modulator Ready for Candidate ProfilingJournal of Medicinal Chemistry · 2025
7. Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical TrialsClinical Infectious Diseases · 2025
8. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its MetabolitesClinical Pharmacology in Drug Development · 2024
9. TLR9 dependent activation by inactivated parapoxvirus ovis (iPPVO) in murine bone marrow-derived dendritic cells is associated with specific strain-dependent dendritic cell subsetsJournal of Innate Immunity · 2024
10. Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail ApproachClinical Pharmacology in Drug Development · 2024
11. A Multicenter Assessment of the Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised PatientsOpen Forum Infectious Diseases · 2024
12. Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy SubjectsClinical Pharmacology in Drug Development · 2024
13. Computational Studies towards the Optimization of the Synthesis of 1,2,4‐Triazolo[1,5‐a]pyridine‐2‐carboxylate: Advantages of Continuous Flow ProcessingEuropean Journal of Organic Chemistry · 2023
14. Nature-inspired and medicinally relevant short peptidesExploration of Drug Science · 2023
15. First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose, Food‐Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase‐Primase Inhibitor Against Herpes Simplex Virus in Healthy SubjectsClinical Pharmacology in Drug Development · 2023
16. EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data: a Delphi approachThe Lancet Regional Health - Europe · 2022
17. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus InfectionsJournal of Medicinal Chemistry · 2022
18. Identification of a Novel Pseudo‐Natural Product Type IV IDO1 Inhibitor ChemotypeAngewandte Chemie International Edition · 2022
19. Identification of a Novel Pseudo‐Natural Product Type IV IDO1 Inhibitor ChemotypeAngewandte Chemie · 2022
20. Protein purification strategies must consider downstream applications and individual biological characteristicsMicrobial Cell Factories · 2022